{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"232.6"},{"groupId":"OG001","spread":"26","value":"219.0"},{"groupId":"OG002","spread":"37","value":"231.2"},{"groupId":"OG003","spread":"56","value":"262.0"},{"groupId":"OG004","spread":"31","value":"209.0"},{"groupId":"OG005","spread":"26","value":"215.5"},{"groupId":"OG006","spread":"16","value":"284.2"},{"groupId":"OG007","spread":"29","value":"218.6"},{"groupId":"OG009","spread":"27","value":"194.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"9"}],"units":"Participants"}],"title":"Cycle 1/Day1-1 Hour/End Of Infusion (EOI)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52","value":"63.60"},{"groupId":"OG001","spread":"65","value":"59.86"},{"groupId":"OG002","spread":"84","value":"61.49"},{"groupId":"OG003","spread":"78","value":"73.57"},{"groupId":"OG004","spread":"43","value":"69.14"},{"groupId":"OG005","spread":"33","value":"60.03"},{"groupId":"OG006","spread":"36","value":"51.85"},{"groupId":"OG007","spread":"25","value":"45.69"},{"groupId":"OG009","spread":"45","value":"34.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"10"}],"units":"Participants"}],"title":"Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84","value":"212.1"},{"groupId":"OG001","spread":"26","value":"226.1"},{"groupId":"OG002","spread":"31","value":"253.6"},{"groupId":"OG003","spread":"33","value":"279.4"},{"groupId":"OG004","spread":"26","value":"238.9"},{"groupId":"OG005","spread":"29","value":"241.9"},{"groupId":"OG006","spread":"27","value":"324.6"},{"groupId":"OG007","spread":"23","value":"221.2"},{"groupId":"OG009","spread":"24","value":"193.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"9"}],"units":"Participants"}],"title":"Cycle 1/Day15-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"276.0"},{"groupId":"OG001","spread":"33","value":"229.0"},{"groupId":"OG002","spread":"31","value":"267.9"},{"groupId":"OG003","spread":"72","value":"255.5"},{"groupId":"OG004","spread":"30","value":"223.4"},{"groupId":"OG005","spread":"18","value":"292.0"},{"groupId":"OG006","spread":"23","value":"302.5"},{"groupId":"OG007","spread":"29","value":"222.0"},{"groupId":"OG008","spread":"20","value":"200.1"},{"groupId":"OG009","spread":"16","value":"203.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"title":"Cycle 2/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18","value":"258.4"},{"groupId":"OG001","spread":"20","value":"232.8"},{"groupId":"OG002","spread":"16","value":"285.6"},{"groupId":"OG003","spread":"79","value":"303.1"},{"groupId":"OG004","spread":"22","value":"209.5"},{"groupId":"OG005","spread":"27","value":"283.0"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG006","spread":"NA","value":"215.0"},{"groupId":"OG007","spread":"18","value":"273.5"},{"groupId":"OG008","spread":"13","value":"206.9"},{"groupId":"OG009","spread":"237","value":"97.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"title":"Cycle 4/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"248.4"},{"groupId":"OG001","spread":"20","value":"211.1"},{"groupId":"OG002","spread":"121","value":"193.2"},{"groupId":"OG003","spread":"126","value":"512.8"},{"groupId":"OG004","spread":"28","value":"217.1"},{"groupId":"OG005","spread":"18","value":"305.9"},{"groupId":"OG006","spread":"3","value":"332.9"},{"groupId":"OG007","spread":"42","value":"275.2"},{"groupId":"OG008","spread":"17","value":"208.3"},{"groupId":"OG009","spread":"11","value":"218.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"title":"Cycle 6/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48","value":"230.0"},{"groupId":"OG001","spread":"39","value":"180.5"},{"groupId":"OG002","spread":"14","value":"328.1"},{"groupId":"OG003","spread":"14","value":"248.4"},{"groupId":"OG004","spread":"20","value":"228.1"},{"groupId":"OG005","spread":"73","value":"187.2"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG006","spread":"NA","value":"335.0"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG007","spread":"NA","value":"102.0"},{"groupId":"OG008","spread":"14","value":"251.2"},{"groupId":"OG009","spread":"374","value":"89.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"title":"Cycle 10/Day1-1 Hour/EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"10"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"OG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least one dose of study drug and who had at least one of the PK concentrations for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points. For ''Phase 2 1L NSCLC: Utomilumab then Utomilumab + Avelumab'' reporting group PK sampling started from Cycle 2 Day 1.","reportingStatus":"POSTED","timeFrame":"1-hour post-dose (at end of infusion) on Day 1,15 of Cycle 1; Day 8 of Cycle 1 (non-dosing); Day 1 of Cycle 2, 4, 6, 10. For ''Phase 2 1L NSCLC: Utomilumab then Utomilumab + Avelumab'' reporting group: Day 1 of Cycle 2, 4, 6, 10","title":"Maximum Observed Plasma Concentration (Cmax) of Avelumab in Combination A","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}